Skip to content

Construction of an early diagnosis model of pancreatic cancer based on dysbindin immunoassay kit

Construction of an early diagnosis model of pancreatic cancer based on dysbindin immunoassay kit

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036512
Enrollment
Unknown
Registered
2020-08-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

on&#32
dysbindin&#32
Gold Standard:Pathological diagnosis
early&#32
diagnosis&#32
model&#32
of&#32
cancer&#32
based&#32

Sponsors

The Third Affiliated Hospital of Second Militory Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Agreed to participate in the research object of this project; 2. Newly diagnosed cases; 3. The patients with pancreatic ductal adenocarcinoma diagnosed by pathology; 4. Keep the fasting venous serum samples before treatment; 5. Subjects with complete clinical data; 6. Aged >= 18 years.

Exclusion criteria

Exclusion criteria: 1. Patients with coronary heart disease, liver cirrhosis, renal insufficiency and metabolic diseases; 2. Patients who have used special drugs in the past 2 weeks; 3. Patients with severe stress reaction, history of surgery or blood transfusion in the past six months; 4. Subjects with history of other malignant tumors;

Design outcomes

Primary

MeasureTime frame
ROC curve;SEN, SPE, ACC;

Countries

China

Contacts

Public ContactCheng Fang

The Third Affiliated Hospital of second militory Medical University

fangchengsurgery@163.com+86 15221853519

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026